Serum Institute to begin production of Sputnik V vaccine in September
Russia's Sputnik V coronavirus vaccine developers and Serum Institute of India (SII) have announced plans to start producing the vaccine in India in September.
Pune: India's leading vaccine manufacturer Serum Institute of India (SII) will begin production of Covid vaccine Sputnik V in September. Also, some other manufacturers are ready to produce the Russian vaccine in India, stated Kirill Dmitriev, CEO, Russian Direct Investment Fund.
Promoting the vaccine globally, Russia's sovereign wealth fund stated that the parties intend to produce over 300 million doses in India per year, the leading production hub for Sputnik V.
The parties intend to produce over 300 million doses of the vaccine in India per year with the first batch expected in September 2021, the Russian Direct Investment Fund (RDIF) said in a statement.
Serum has already received cell and vector samples from the Gamaleya Center as a part of the technical transfer process,.
With their import approved by the Drug Controller General of India (DCGI), the cultivation process has begun, RDIF announced.
Earlier, in India, RDIF has reached agreements with a number of pharmaceutical companies such as Gland Pharma, Hetero Biopharma, Panacea Biotec, Stelis Biopharma, Virchow Biotech and Morepen to manufacture the Russian vaccine in India.
Dr Reddy’s is the only company to hold the sole distribution rights for the first 250 million doses of Sputnik V in India.
The Sputnik V vaccine, which was the third vaccine to get approval in India, was launched on a soft pilot basis earlier on May 14. The nationwide soft launch of Sputnik V has reached over 50 cities and towns across the nation.
NOTE: Asianet News humbly requests everyone to wear masks, sanitize, maintain social distancing and get vaccinated as soon as eligible. Together we can and will break the chain #ANCares #IndiaFightsCorona